Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Dr. Judith Balmaña, Dr. Rebecca Dent, Prof. Simon Boulton, Prof. Sibylle Loibl, Prof. Eric Pujade-Lauraine, Prof. Charlie Gourley, Dr. Violeta Serra, Prof. Jonathan A. Ledermann
Published in the Journal of Clinical Oncology, a review paper authored by a multidisciplinary group of international experts in DNA Damage Response (DDR) and PARP inhibition
Now Published |
10 min

I agree that this educational programme:
Was valuable to me:
1/3
Other programmes of interest
Other programmes developed by Dr. Judith Balmaña

Dr. Judith Balmaña
Medical Oncologist
Vall d'Hebron University Hospital
Spain
Other programmes developed by Dr. Rebecca Dent

Dr. Rebecca Dent
Medical Oncologist
National Cancer Center Singapore
Singapore
Other programmes developed by Prof. Simon Boulton

Prof. Simon Boulton
Senior Scientist
Francis Crick Institute
United Kingdom (UK)
Other programmes developed by Prof. Eric Pujade-Lauraine

Prof. Eric Pujade-Lauraine
Gynaecologic Oncologist
Hôpital Hôtel-Dieu
France
Other programmes developed by Prof. Charlie Gourley

Prof. Charlie Gourley
Medical Oncologist
CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Re...
United Kingdom (UK)
Other programmes developed by Dr. Violeta Serra

Dr. Violeta Serra
Senior Scientist
Vall d'Hebron Institute of Oncology
Spain
Other programmes developed by Prof. Jonathan A. Ledermann

Prof. Jonathan A. Ledermann
Medical Oncologist
UCL Cancer Institute
United Kingdom (UK)